{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T06:21:29Z","timestamp":1791440489242,"version":"4.3.3"},"reference-count":177,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.jconrel.2020.05.044","type":"journal-article","created":{"date-parts":[[2020,5,27]],"date-time":"2020-05-27T22:03:45Z","timestamp":1590617025000},"page":"25-37","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":63,"special_numbering":"C","title":["Neurotherapeutic applications of nanomedicine for treating Alzheimer's disease"],"prefix":"10.1016","volume":"325","author":[{"given":"Barnabas","family":"Wilson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kannoth Mukundan","family":"Geetha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2020.05.044_bb0005","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1097\/01.mjt.0000208274.80496.f1","article-title":"Alzheimer\u2019s disease and its management: a review","volume":"13","author":"Samanta","year":"2006","journal-title":"Am. J. Ther."},{"issue":"2015","key":"10.1016\/j.jconrel.2020.05.044_bb0010","first-page":"332","article-title":"Alzheimer\u2019s disease facts and figures","volume":"11","author":"Alzheimer\u2019\u2019s Association","year":"2015","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.jconrel.2020.05.044_bb0015","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1212\/WNL.0b013e31828726f5","article-title":"Alzheimer\u2019s disease in the United States (2010\u20132050) estimated using the 2010 census","volume":"80","author":"Hebert","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.jconrel.2020.05.044_bb0020","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.cell.2009.05.042","article-title":"Bridging physiology and pathology in AD","volume":"137","author":"Kim","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.jconrel.2020.05.044_bb0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jalz.2016.07.150","article-title":"The worldwide cost of dementia 2015 and comparisons with 2010","volume":"13","author":"Wimo","year":"2017","journal-title":"Alzheimer\u2019s Dement."},{"key":"10.1016\/j.jconrel.2020.05.044_bb0030","doi-asserted-by":"crossref","first-page":"499","DOI":"10.2217\/nnm.09.29","article-title":"Brain targeting PBCA nanoparticles and the blood-brain barrier","volume":"4","author":"Wilson","year":"2009","journal-title":"Nanomedicine (London)"},{"key":"10.1016\/j.jconrel.2020.05.044_bb0035","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.2217\/nnm.11.114","article-title":"Therapeutic compliance of nanomedicine in Alzheimer\u2019s Disease","volume":"6","author":"Wilson","year":"2011","journal-title":"Nanomedicine (London)"},{"key":"10.1016\/j.jconrel.2020.05.044_bb0040","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/S0306-4522(02)00697-8","article-title":"Inhibition of protein phosphatase 1-induced tau hyperphosphorylation and impairment of spatial memory retention in rats","volume":"118","author":"Sun","year":"2003","journal-title":"Neuroscience"},{"key":"10.1016\/j.jconrel.2020.05.044_bb0045","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1016\/0022-510X(82)90045-4","volume":"57","author":"Wilcock","year":"1982","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.jconrel.2020.05.044_bb0050","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1007\/BF00229886","article-title":"Attentional functions of the forebrain cholinergic systems: effects of intraventricular hemicholinium, physostigmine, basal forebrain and intracortical grafts on a multiple-choice serial reaction time task","volume":"89","author":"Muir","year":"1992","journal-title":"Exp. Brain Res."},{"key":"10.1016\/j.jconrel.2020.05.044_bb0055","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1101\/lm.64604","article-title":"Cholinergic modulation of the hippocampus during encoding and retrieval of tone\/shock-induced fear conditioning","volume":"11","author":"Rogers","year":"2004","journal-title":"Learn. Mem."},{"key":"10.1016\/j.jconrel.2020.05.044_bb0060","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/nn835","article-title":"Extrasynaptic NMDARs oppose synaptic NMDARs by triggering CREB shut-off and cell death pathways","volume":"5","author":"Hardingham","year":"2002","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.jconrel.2020.05.044_bb0065","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1126\/science.283.5398.70","article-title":"Blockade of NMDA receptors and apoptotic neurodegeneration in the developing brain","volume":"283","author":"Ikonomidou","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.jconrel.2020.05.044_bb0070","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1002\/ana.410190202","article-title":"Glutamate and the pathophysiology of hypoxic-ischemic brain damage","volume":"19","author":"Rothman","year":"1986","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jconrel.2020.05.044_bb0075","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s00221-011-2870-1","article-title":"Axonal transport of APP and the spatial regulation of APP cleavage and function in neuronal cells","volume":"217","author":"Brunholz","year":"2012","journal-title":"Exp. Brain Res."},{"key":"10.1016\/j.jconrel.2020.05.044_bb0080","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1177\/0891988710383571","article-title":"Genetics of Alzheimer\u2019s disease","volume":"23","author":"Bekris","year":"2010","journal-title":"J. Geriatr. Psychiatry Neurol."},{"key":"10.1016\/j.jconrel.2020.05.044_bb0085","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1002\/ana.410330306","article-title":"Risk factors for late-onset Alzheimer\u2019s disease: a population-based, case control study","volume":"33","author":"Fratiglioni","year":"1993","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jconrel.2020.05.044_bb0090","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1212\/WNL.43.8.1467","article-title":"Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer\u2019s disease","volume":"43","author":"Saunders","year":"1993","journal-title":"Neurology"},{"key":"10.1016\/j.jconrel.2020.05.044_bb0095","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1038\/sj.npp.1300690","article-title":"A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment","volume":"30","author":"Thal","year":"2005","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.jconrel.2020.05.044_bb0100","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1212\/WNL.43.8.1609","article-title":"Clinical trial of indomethacin in Alzheimer\u2019s disease","volume":"43","author":"Rogers","year":"1993","journal-title":"Neurology"},{"key":"10.1016\/j.jconrel.2020.05.044_bb0105","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1212\/WNL.53.1.197","article-title":"A double-blind, placebo-controlled trial of diclofenac\/misoprostol in Alzheimer\u2019s disease","volume":"53","author":"Scharaf","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.jconrel.2020.05.044_bb0110","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1001\/jama.289.21.2819","article-title":"Effects of rofecoxib or naproxen vs placebo on Alzheimer\u2019s disease progression","volume":"289","author":"Aisen","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.jconrel.2020.05.044_bb0115","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1001\/jama.2009.1866","article-title":"Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer\u2019s disease: a randomized controlled trial","volume":"302","author":"Green","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.jconrel.2020.05.044_bb0120","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/j.1600-0404.2006.00685.x","article-title":"Cholesterol as a risk factor for Alzheimer\u2019s disease \u2013 epidemiological evidence","volume":"185","author":"Kivipelto","year":"2006","journal-title":"Acta Neurol. Scand. Suppl."},{"key":"10.1016\/j.jconrel.2020.05.044_bb0125","doi-asserted-by":"crossref","first-page":"641","DOI":"10.3233\/JAD-2008-15410","article-title":"The early and ongoing experience with the cholesterol-fed rabbit as a model of Alzheimer\u2019s disease: the old, the new and the pilot","volume":"15","author":"Sparks","year":"2008","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.jconrel.2020.05.044_bb0130","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1136\/ebmh1069","article-title":"Atorvastatin does not slow cognitive decline in patients with mild to moderate probable Alzheimer\u2019s disease who are taking donepezil","volume":"13","author":"Fillit","year":"2010","journal-title":"Evid. Based Ment. Health"},{"key":"10.1016\/j.jconrel.2020.05.044_bb0135","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1007\/s12603-009-0106-x","article-title":"Effect of tramiprosate in patients with mild to moderate Alzheimer\u2019s disease: exploratory analysis of the MRI sub-group of the Alphase study","volume":"13","author":"Gauthier","year":"2009","journal-title":"J. Nutr. Health Aging"},{"key":"10.1016\/j.jconrel.2020.05.044_bb0140","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s12603-009-0045-6","article-title":"What we have learned from the xaliproden Sanofi-Aventis trials?","volume":"13","author":"Douillet","year":"2009","journal-title":"J. Nutr. Health Aging"},{"key":"10.1016\/j.jconrel.2020.05.044_bb0145","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1001\/jama.2008.683","article-title":"Ginkgo biloba for prevention of dementia: a randomized controlled trial","volume":"300","author":"DeKosky","year":"2008","journal-title":"JAMA"},{"key":"10.1016\/j.jconrel.2020.05.044_bb0150","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1023\/A:1006995910836","article-title":"Tight junctions of the blood-brain barrier","volume":"20","author":"Kniesel","year":"2000","journal-title":"Cell. Mol. Neurobiol."},{"key":"10.1016\/j.jconrel.2020.05.044_bb0155","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jneumeth.2018.10.015","article-title":"Drug targeting strategies into the brain for treating neurological diseases","volume":"311","author":"Wilson","year":"2019","journal-title":"J. Neurosci. Meth."},{"key":"10.1016\/j.jconrel.2020.05.044_bb0160","series-title":"Advances in Non-Invasive Drug Delivery Into the Brain","first-page":"62","article-title":"Nanoparticle-based drug delivery for Alzheimer\u2019s disease","author":"Wilson","year":"2015"},{"key":"10.1016\/j.jconrel.2020.05.044_bb0165","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.nbd.2003.12.016","article-title":"The blood-brain barrier: an overview: structure, regulation, and clinical implications","volume":"16","author":"Ballabh","year":"2004","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.jconrel.2020.05.044_bb0170","doi-asserted-by":"crossref","first-page":"7794","DOI":"10.1200\/JCO.2005.04.937","article-title":"Phase III trial of nanoparticles albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer","volume":"23","author":"Gradishar","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2020.05.044_bb0175","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.ijbiomac.2012.07.014","article-title":"Nanoparticles based on albumin: preparation, characterization and the use for 5-flurouracil delivery","volume":"51","author":"Wilson","year":"2012","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.jconrel.2020.05.044_bb0180","doi-asserted-by":"crossref","first-page":"433","DOI":"10.2217\/nnm-2019-0366","article-title":"Artificial intelligence and related technologies enabled nanomedicine for advanced cancer treatment","volume":"15","author":"Wilson","year":"2020","journal-title":"Nanomedicine (London)"},{"key":"10.1016\/j.jconrel.2020.05.044_bb0185","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.ijbiomac.2012.07.014","article-title":"Nanoparticles based on albumin: preparation, characterization and the use for 5-flurouracil delivery","volume":"51","author":"Wilson","year":"2012","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.jconrel.2020.05.044_bb0190","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.ijpharm.2014.05.056","article-title":"Albumin nanoparticles for the delivery of gabapentin: preparation, characterization and pharmacodynamic studies","volume":"473","author":"Wilson","year":"2014","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2020.05.044_bb0195","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.ijbiomac.2015.09.015","article-title":"Development of albumin-based nanoparticles for the delivery of abacavir","volume":"81","author":"Wilson","year":"2015","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.jconrel.2020.05.044_bb0200","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.ijpharm.2005.11.040","article-title":"Influence of particle size on transport of methotrexate across blood-brain barrier by polysorbate 80-coated polybutylcyanoacrylate nanoparticles","volume":"310","author":"Gao","year":"2006","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2020.05.044_bb0205","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.colsurfb.2008.07.004","article-title":"Biodistribution of colloidal gold nanoparticles after intravenous administration: effect of particle size","volume":"66","author":"Sonavane","year":"2008","journal-title":"Colloids Surf. B Biointerf."},{"key":"10.1016\/j.jconrel.2020.05.044_bb0210","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S0169-409X(00)00122-8","article-title":"Nanoparticulate systems for brain delivery of drugs","volume":"47","author":"Kreuter","year":"2001","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2020.05.044_bb0215","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jconrel.2006.12.012","article-title":"Covalent attachment of apolipoprotein A-I and apolipoprotein B-100 to albumin nanoparticles enables drug transport into the brain","volume":"118","author":"Kreuter","year":"2007","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2020.05.044_bb0220","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2165\/00003088-199528060-00003","article-title":"Clinical pharmacokinetics of tacrine","volume":"28","author":"Madden","year":"1995","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.jconrel.2020.05.044_bb0225","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1093\/ageing\/20.2.129","article-title":"Effects of tetrahydroaminoacridine on liver function in patients with Alzheimer\u2019s disease","volume":"20","author":"O\u2019Brien","year":"1991","journal-title":"Age Aging"},{"key":"10.1016\/j.jconrel.2020.05.044_bb0230","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1001\/jama.280.20.1777","article-title":"Cholinesterase inhibition for Alzheimer\u2019s disease: a meta-analysis of the tacrine trials. Dementia Trialists collaboration","volume":"280","author":"Qizilbash","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.jconrel.2020.05.044_bb0235","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ejpb.2008.03.009","article-title":"Targeted delivery of tacrine into the brain with polysorbate 80-coated poly(n-butylcyanoacrylate) nanoparticles","volume":"70","author":"Wilson","year":"2008","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jconrel.2020.05.044_bb0240","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.ejps.2011.10.002","article-title":"Albumin nanoparticles carrying cyclodextrins for nasal delivery of the anti-Alzheimer\u2019s drug tacrine","volume":"44","author":"Luppi","year":"2011","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2020.05.044_bb0245","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.pnpbp.2004.10.006","article-title":"Central acetylcholinesterase inhibitors in the treatment of chronic traumatic brain injury-clinical experience in 111 patients","volume":"29","author":"Tenovuo","year":"2005","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.jconrel.2020.05.044_bb0250","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1185\/030079906X162791","article-title":"Strategies to improve tolerability of rivastigmine: a case series","volume":"23","author":"Venkatesh","year":"2007","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.jconrel.2020.05.044_bb0255","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.brainres.2008.01.039","article-title":"Poly(n-butylcyanoacrylate) nanoparticles coated with polysorbate 80 for the targeted delivery of rivastigmine into the brain to treat Alzheimer\u2019s disease","volume":"1200","author":"Wilson","year":"2008","journal-title":"Brain Res."},{"key":"10.1016\/j.jconrel.2020.05.044_bb0260","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ejps.2012.04.013","article-title":"Development and evaluation of rivastigmine loaded chitosan nanoparticles for brain targeting","volume":"47","author":"Fazil","year":"2012","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2020.05.044_bb0265","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.ejpb.2010.07.007","article-title":"Rivastigmine-loaded PLGA and PBCA nanoparticles: preparation, optimization, characterization, in vitro and pharmacodynamic studies","volume":"76","author":"Joshi","year":"2010","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jconrel.2020.05.044_bb0270","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.ijpharm.2013.05.009","article-title":"Enhanced brain distribution and pharmacodynamics of rivastigmine by liposomes following intranasal administration","volume":"452","author":"Yang","year":"2013","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2020.05.044_bb0275","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1023\/A:1022419712453","article-title":"The cognitive psychopharmacology of Alzheimer\u2019s disease: focus on cholinergic systems","volume":"23","author":"Lawrence","year":"1998","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.jconrel.2020.05.044_bb0280","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1016\/S0149-2918(03)80168-6","article-title":"An open-label extension trial of galantamine in patients with probable vascular dementia and mixed dementia","volume":"25","author":"Erkinjuntti","year":"2003","journal-title":"Clin. Ther."},{"key":"10.1016\/j.jconrel.2020.05.044_bb0285","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1212\/WNL.54.12.2269","article-title":"A 5-month, randomized, placebo-controlled trial of galantamine in AD. The galantamine USA-10 study group","volume":"54","author":"Tariot","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.jconrel.2020.05.044_bb0290","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1136\/bmj.321.7274.1445","article-title":"Efficacy and safety of galantamine in patients with mild to moderate Alzheimer\u2019s disease: multicenter randomized controlled trial","volume":"321","author":"Wilcock","year":"2000","journal-title":"BMJ"},{"key":"10.1016\/j.jconrel.2020.05.044_bb0295","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1016\/S0149-2918(03)80168-6","article-title":"An open-label extension trial of galantamine in patients with probable vascular dementia and mixed dementia","volume":"25","author":"Erkinjuntti","year":"2003","journal-title":"Clin. Ther."},{"key":"10.1016\/j.jconrel.2020.05.044_bb0300","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1016\/S0149-2918(03)80171-6","article-title":"Economic evaluation of galantamine in the treatment of mild to moderate Alzheimer\u2019s disease in the United States","volume":"25","author":"Migliaccio-Walle","year":"2003","journal-title":"Clin. Ther."},{"key":"10.1016\/j.jconrel.2020.05.044_bb0305","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.neuint.2010.07.007","article-title":"Protective effects of galantamine against A\u03b2 induced PC12 cell apoptosis by preventing mitochondrial dysfunction and endoplasmic stress","volume":"57","author":"Liu","year":"2010","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.jconrel.2020.05.044_bb0310","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.ijpharm.2013.03.037","article-title":"Ligand-functionalized nanoliposomes for targeted delivery of galantamine","volume":"448","author":"Mufamadi","year":"2013","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2020.05.044_bb0315","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.3109\/03639045.2015.1062897","article-title":"Complexation as an approach to entrap cationic drugs into cationic nanoparticles administered intranasally for Alzheimer\u2019s disease management: preparation and detection in rat brain","volume":"41","author":"Hanafy","year":"2015","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.jconrel.2020.05.044_bb0320","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.3109\/10717544.2015.1089956","article-title":"Galantamine-loaded solid-lipid nanoparticles for enhanced brain delivery: preparation, characterization, in vitro and in vivo evaluations","volume":"23","author":"Misra","year":"2016","journal-title":"Drug Deliv."},{"key":"10.1016\/j.jconrel.2020.05.044_bb0325","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.etap.2012.04.012","article-title":"Pharmacokinetic behavior and efficiency of acetylcholinesterase inhibition in rat brain after intranasal administration of galantamine hydrobromide loaded flexible liposomes","volume":"34","author":"Li","year":"2012","journal-title":"Environ. Toxicol. Pharmacol."},{"key":"10.1016\/j.jconrel.2020.05.044_bb0330","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1159\/000051272","article-title":"Chronic donepezil treatment is associated with slowed cognitive decline in Alzheimer\u2019s disease","volume":"12","author":"Doody","year":"2001","journal-title":"Dement. Geriatr. Cogn. Disord."},{"key":"10.1016\/j.jconrel.2020.05.044_bb0335","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1212\/WNL.57.3.481","article-title":"A 1-year placebo-controlled preservation of function. Survival study of donepezil in Alzheimer\u2019s disease patients","volume":"57","author":"Mohs","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.jconrel.2020.05.044_bb0340","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1212\/WNL.57.3.489","article-title":"A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate Alzheimer\u2019s disease","volume":"57","author":"Winblad","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.jconrel.2020.05.044_bb0345","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1161\/01.STR.0000091396.95360.E1","article-title":"Efficacy and tolerability of donepezil in vascular dementia-positive results of a 24-week, multicentre, international, randomized, placebo-controlled clinical trial","volume":"34","author":"Black","year":"2003","journal-title":"Stroke"},{"key":"10.1016\/j.jconrel.2020.05.044_bb0350","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1345\/aph.10192","article-title":"Successful use of donepezil for the treatment of dementia with Lewy bodies","volume":"35","author":"Rojas-Fernandez","year":"2001","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.jconrel.2020.05.044_bb0355","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s40262-013-0038-9","article-title":"Pharmacodynamic, pharmacokinetic and pharmacogenetic aspects of drugs used in the treatment of Alzheimer\u2019s disease","volume":"52","author":"Noetzli","year":"2013","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.jconrel.2020.05.044_bb0360","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.ijbiomac.2014.03.022","article-title":"Donepezil nanosuspension intended for nose to brain targeting: in vitro and in vivo safety evaluation","volume":"67","author":"Bhavna","year":"2014","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.jconrel.2020.05.044_bb0365","doi-asserted-by":"crossref","first-page":"278","DOI":"10.3109\/03639045.2012.758130","article-title":"Preparation, characterization, in vivo biodistribution and pharmacokinetic studies of donepezil-loaded PLGA nanoparticles for brain targeting","volume":"40","author":"Bhavana","year":"2014","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.jconrel.2020.05.044_bb0370","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s00702-016-1527-4","article-title":"Donepezil loaded PLGA-b-PEG nanoparticles: their ability to induce destabilization of amyloid fibrils and to cross blood-brain barrier in vitro","volume":"124","author":"Bayasal","year":"2017","journal-title":"J. Neural Transm. (Vienna)"},{"key":"10.1016\/j.jconrel.2020.05.044_bb0375","first-page":"4","article-title":"Copper, iron and zinc in Alzheimer\u2019s disease senile plaques","volume":"158","author":"Lovel","year":"1998","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.jconrel.2020.05.044_bb0380","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/j.1749-6632.1994.tb21837.x","article-title":"Induction of production of nitric oxide in microglial cells by insoluble form of aluminium","volume":"738","author":"Garrel","year":"1994","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.jconrel.2020.05.044_bb0385","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1016\/0140-6736(91)92978-B","article-title":"Intramuscular desferrioxamine in patients with Alzheimer\u2019s disease","volume":"337","author":"Craper McLachlan","year":"1991","journal-title":"Lancet"},{"key":"10.1016\/j.jconrel.2020.05.044_bb0390","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1001\/archneur.60.12.1685","article-title":"Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer\u2019s disease: a pilot phase 2 clinical trial","volume":"60","author":"Ritchie","year":"2003","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.jconrel.2020.05.044_bb0395","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.neulet.2009.03.064","article-title":"Nnaoparticle-chelator conjugates as inhibitors of amyloid-\u03b2 aggregation and neurotoxicity: a novel therapeutic approach for Alzheimer\u2019s disease","volume":"455","author":"Liu","year":"2009","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.jconrel.2020.05.044_bb0400","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.ejpb.2004.07.009","article-title":"Novel Dpenicillamine carrying nanoparticles for metal chelation therapy in Alzheimer\u2019s and other CNS diseases","volume":"59","author":"Cui","year":"2005","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jconrel.2020.05.044_bb0405","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.bpobgyn.2008.10.004","article-title":"Alzheimer\u2019s disease in women","volume":"23","author":"Craig","year":"2009","journal-title":"Best Pract. Res. Clin. Obstet. Gynaecol."},{"key":"10.1016\/j.jconrel.2020.05.044_bb0410","doi-asserted-by":"crossref","first-page":"S131","DOI":"10.1016\/j.jalz.2007.10.009","article-title":"More than a decade of estrogen neuroprotection","volume":"4","author":"Simpkins","year":"2008","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.jconrel.2020.05.044_bb0415","first-page":"99","article-title":"Long-term estrogen replacement therapy in female patients with dementia of the Alzheimer\u2019s type","volume":"6","author":"Ohkura","year":"1995","journal-title":"Dementia"},{"key":"10.1016\/j.jconrel.2020.05.044_bb0420","first-page":"315","article-title":"Can estrogen keep you smart? Evidence from clinical studies","volume":"24","author":"Sherwin","year":"1999","journal-title":"J. Psychiatry Neurosci."},{"key":"10.1016\/j.jconrel.2020.05.044_bb0425","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.ejpb.2008.07.005","article-title":"Preparation of estradiol chitosan nanoparticles for improving nasal absorption and brain targeting","volume":"70","author":"Wang","year":"2008","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jconrel.2020.05.044_bb0430","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.jconrel.2010.11.013","article-title":"Development and evaluation of polymer nanoparticles for oral delivery of estradiol to rat brain in a model of Alzheimer\u2019s pathology","volume":"150","author":"Mittal","year":"2011","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2020.05.044_bb0435","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/S0047-6374(01)00384-0","article-title":"Reactive oxygen and nitrogen species and cellular and organismal decline: amelioration with melatonin","volume":"123","author":"Reiter","year":"2002","journal-title":"Mech. Ageing Dev."},{"key":"10.1016\/j.jconrel.2020.05.044_bb0440","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.ijpharm.2004.11.003","article-title":"Protective properties of melatonin-loaded nanoparticles against lipid peroxidation","volume":"289","author":"Schaffazick","year":"2005","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2020.05.044_bb0445","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.ejpb.2007.11.010","article-title":"Incorporation of polymeric nanocapsules improves the antioxidant effect of melatonin against lipid peroxidation in mice brain and liver","volume":"69","author":"Schaffazick","year":"2008","journal-title":"Eur. J. Pharm. Bioharm."},{"key":"10.1016\/j.jconrel.2020.05.044_bb0450","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.biomaterials.2009.09.104","article-title":"Trimethylated chitosan-conjucated PLGA nanopartiles for the delivery of drugs to the brain","volume":"31","author":"Wang","year":"2010","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2020.05.044_bb0455","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.bbrc.2008.06.035","article-title":"TiO2 nanoparticles promote beta-amyloid fibrillation in vitro","volume":"373","author":"Wu","year":"2008","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.jconrel.2020.05.044_bb0460","doi-asserted-by":"crossref","first-page":"15437","DOI":"10.1021\/ja8041806","article-title":"Inhibition of amyloid beta protein fibrillation by polymeric nanoparticles","volume":"130","author":"Cabaleiro-Lago","year":"2008","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.jconrel.2020.05.044_bb0465","doi-asserted-by":"crossref","first-page":"5110","DOI":"10.1002\/anie.201007824","article-title":"Inhibition of amyloid peptide fibrillation by inorganic nanoparticles: functional similarities with proteins","volume":"50","author":"Yoo","year":"2011","journal-title":"Angew. Chem. Int. Edit."},{"key":"10.1016\/j.jconrel.2020.05.044_bb0470","doi-asserted-by":"crossref","first-page":"4443","DOI":"10.1016\/j.biomaterials.2012.03.024","article-title":"Effect of surface-functionalized nanoparticles on the elongation phase of beta-amyloid (1-40) fibrillogenesis","volume":"33","author":"Chan","year":"2012","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2020.05.044_bb0475","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/j.1749-6632.1998.tb11180.x","article-title":"VIP neurotrophism in the central nervous system: multiple effectors and identification of a femtomolar-acting neuropeptide","volume":"865","author":"Brenneman","year":"1998","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.jconrel.2020.05.044_bb0480","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1002\/glia.20681","article-title":"Vasoactive intestinal peptide protects against beta-amyloid- induced neurodegeneration by inhibiting microglia activation at multiple levels","volume":"56","author":"Delgado","year":"2008","journal-title":"Glia"},{"key":"10.1016\/j.jconrel.2020.05.044_bb0485","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.jconrel.2007.05.026","article-title":"Brain delivery of vasoactive intestinal peptide enhanced with the nanoparticles conjugated with wheat germ agglutinin following intranasal administration","volume":"121","author":"Gao","year":"2007","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2020.05.044_bb0490","doi-asserted-by":"crossref","first-page":"19567","DOI":"10.1073\/pnas.1319297110","article-title":"BMP9 ameliorates amyloidosis and the cholinergic defect in a mouse model of Alzheimer\u2019s disease","volume":"110","author":"Burke","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jconrel.2020.05.044_bb0495","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jns.2014.06.037","article-title":"Intranasal growth factor attenuates tau phosphorylation in brain after traumatic brain injury in rats","volume":"345","author":"Ly","year":"2014","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.jconrel.2020.05.044_bb0500","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.15252\/emmm.201404228","article-title":"Insulin-like growth factor 2 reerses memory and synaptic deficits in APP transgenic mice","volume":"6","author":"Pascual-Lucas","year":"2014","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.jconrel.2020.05.044_bb0505","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1080\/10611860903112842","article-title":"Brain targeting of nerve growth factor using poly(butyl cyanoacrylate) nanoparticles","volume":"17","author":"Kurakhmaeva","year":"2009","journal-title":"J. Drug Target."},{"key":"10.1016\/j.jconrel.2020.05.044_bb0510","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1007\/s11095-012-0915-1","article-title":"Intranasal treatment of central nervous system dysfunction in humans","volume":"30","author":"Chapman","year":"2013","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2020.05.044_bb0515","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.addr.2011.11.002","article-title":"Intranasal delivery of biologicals to the central nervous system","volume":"64","author":"Lochhead","year":"2012","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2020.05.044_bb0520","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.ejphar.2012.09.020","article-title":"Effect of BFGF on neuronal damage induced by sequential treatment of amyloid beta and excitory amino acid in vitro and in vivo","volume":"695","author":"Noshita","year":"2012","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.jconrel.2020.05.044_bb0525","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.ijpharm.2013.11.049","article-title":"Intranasal nanoparticles of basic fibroblast growth factor for brain delivery to treat Alzheimer\u2019s disease","volume":"461","author":"Zhang","year":"2014","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2020.05.044_bb0530","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.jconrel.2013.04.028","article-title":"VEGF-releasing biodegradable nanospheres administered by craniotomy: a novel therapeutic approach in the APP\/Ps1 mouse model of Alzheimer\u2019s disease","volume":"170","author":"Herran","year":"2013","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2020.05.044_bb0535","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1038\/35050110","article-title":"A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer\u2019s disease","volume":"408","author":"Janus","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2020.05.044_bb0540","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jconrel.2005.11.010","article-title":"Novel oral formulation safely improving oral absorption of poorly absorbable drugs: utilization of polyamines and bile acids","volume":"111","author":"Miyake","year":"2006","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2020.05.044_bb0545","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1007\/s11095-008-9600-9","article-title":"Selective contrast enhancement of individual Alzheimer\u2019s disease amyloid plaques using a polyamine and Gd-DOTA conjugated antibody fragment against fibrillar A beta 42 for magnetic resonance molecular imaging","volume":"25","author":"Ramakrishnan","year":"2008","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2020.05.044_bb0550","doi-asserted-by":"crossref","first-page":"13532","DOI":"10.1021\/bi049399k","article-title":"Truncated carboxyl-terminal fragments of beta-amyloid precursor protein are processed to amyloid beta-proteins 40 and 42","volume":"43","author":"Funamoto","year":"2004","journal-title":"Biochemistry"},{"key":"10.1016\/j.jconrel.2020.05.044_bb0555","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.bcp.2010.04.011","article-title":"Molecular imaging and targeted therapies","volume":"80","author":"Morse","year":"2010","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.jconrel.2020.05.044_bb0560","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.jconrel.2011.12.036","article-title":"Targeting the amyloid-\u03b2 antibody in the brain tissue of a mouse model of Alzheimer\u2019s disease","volume":"159","author":"McLean","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2020.05.044_bb0565","doi-asserted-by":"crossref","first-page":"9810","DOI":"10.1073\/pnas.0703137104","article-title":"Liposomal vaccines with conformation-specific amyloid peptide antigens define immune response and efficacy in APP transgenic mice","volume":"104","author":"Muhs","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jconrel.2020.05.044_bb0570","doi-asserted-by":"crossref","first-page":"5242","DOI":"10.1002\/anie.200460437","article-title":"Functionalized carbon nanotubes for plasmid DNA gene delivery","volume":"43","author":"Pantarotto","year":"2004","journal-title":"Angew. Chem. Int. Edn."},{"key":"10.1016\/j.jconrel.2020.05.044_bb0575","doi-asserted-by":"crossref","first-page":"4782","DOI":"10.1002\/anie.200500042","article-title":"Polyethylenimine-grafted multiwalled carbon nanotubes for secure nonvalent immobilization and efficient delivery of DNA","volume":"44","author":"Liu","year":"2005","journal-title":"Agnew. Chem. Int. Edn."},{"key":"10.1016\/j.jconrel.2020.05.044_bb0580","doi-asserted-by":"crossref","first-page":"15638","DOI":"10.1021\/ja0466311","article-title":"Near-infrared fluorescence microscopy of single-walled carbon nanotubes in phagocytic cells","volume":"126","author":"Cherukuri","year":"2004","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.jconrel.2020.05.044_bb0585","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.toxlet.2004.11.004","article-title":"Multi-walled carbon nanotube interactions with human epidermal keratinocytes","volume":"155","author":"Monteiro-Riviere","year":"2005","journal-title":"Toxicol. Lett."},{"key":"10.1016\/j.jconrel.2020.05.044_bb0590","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.toxlet.2005.06.020","article-title":"Multi-walled carbon nanotubes induce T lymphocyte apoptosis","volume":"160","author":"Bottini","year":"2006","journal-title":"Toxicol. Lett."},{"key":"10.1016\/j.jconrel.2020.05.044_bb0595","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.toxlet.2004.08.015","article-title":"Effect of single wall carbon nanotubes on human HEK 293 cells","volume":"155","author":"Cui","year":"2005","journal-title":"Toxicol. Lett."},{"key":"10.1016\/j.jconrel.2020.05.044_bb0600","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.nano.2009.11.007","article-title":"Pharmacological and toxicological target organelles and safe use of single-walled carbon nanotubes as drug carriers in treating Alzheimer\u2019s disease","volume":"6","author":"Yang","year":"2010","journal-title":"Nanomedicine"},{"key":"10.1016\/j.jconrel.2020.05.044_bb0605","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1016\/j.bpj.2011.09.046","article-title":"Carbon nanotube inhibits the formation of \u03b2-sheet-rich oligomers of the Alzheimer\u2019s amyloid-\u03b2 (16-22) peptide","volume":"101","author":"Li","year":"2011","journal-title":"Biophys. J."},{"key":"10.1016\/j.jconrel.2020.05.044_bb0610","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1080\/10717544.2016.1276232","article-title":"Basic concepts and recent advances in nanogels as carriers for medical applications","volume":"24","author":"Neamtu","year":"2017","journal-title":"Drug Deliv."},{"key":"10.1016\/j.jconrel.2020.05.044_bb0615","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.reactfunctpolym.2016.04.019","article-title":"Multifunctionality of self-assembled nanogels of curcumin-hyaluronic acid conjugates on inhibiting amyloid \u03b2-protein fibrillation and cytotoxicity","volume":"104","author":"Jiang","year":"2016","journal-title":"React. Funct. Polym."},{"key":"10.1016\/j.jconrel.2020.05.044_bb0620","doi-asserted-by":"crossref","first-page":"6587","DOI":"10.1016\/j.febslet.2006.11.009","article-title":"Inhibition of the formation of amyloid b-protein fibrils using biocompatible nanogels as artificial chaperones","volume":"580","author":"Ikeda","year":"2006","journal-title":"FEBS Lett."},{"key":"10.1016\/j.jconrel.2020.05.044_bb0625","doi-asserted-by":"crossref","first-page":"3505","DOI":"10.1038\/s41598-018-21933-6","article-title":"Nanogels of dual inhibitor-modified hyaluronic acid function as a potent inhibitor of amyloid \u03b2-protein aggregation and cytotoxicity","volume":"8","author":"Jiang","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jconrel.2020.05.044_bb0630","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1021\/ar300053p","article-title":"Molecular rotors: what lies behind the high sensitivity of the Thioflavin-T fluorescent marker","volume":"45","author":"Amdursky","year":"2012","journal-title":"Acc. Chem. Res."},{"key":"10.1016\/j.jconrel.2020.05.044_bb0635","doi-asserted-by":"crossref","first-page":"16462","DOI":"10.1074\/jbc.C300049200","article-title":"Direct observation of amyloid fibril growth monitored by Thioflavin-T fluorescence","volume":"278","author":"Ban","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jconrel.2020.05.044_bb0640","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/S0304-3940(02)01399-X","article-title":"Electron microscopic analysis of nanoparticles delivering thioflavin-T after intrahippocampal injection in mouse: implications for targeting \u03b2-amyloid in Alzheimer\u2019s disease","volume":"338","author":"Hartig","year":"2003","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.jconrel.2020.05.044_bb0645","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.ijdevneu.2005.11.012","article-title":"Thioflavins released from nanoparticles target fibrillar amyloid beta in the hippocampus of APP\/PS1 transgenic mice","volume":"24","author":"Siegemund","year":"2006","journal-title":"Int. J. Dev. Neurosci."},{"key":"10.1016\/j.jconrel.2020.05.044_bb0650","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1016\/j.biomaterials.2013.10.075","article-title":"Multimodal nanoprobes to target cerebrovascular amyloid in Alzheimer\u2019s disease brain","volume":"35","author":"Jaruszewski","year":"2014","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2020.05.044_bb0655","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.nano.2012.11.004","article-title":"Curcumin-conjugated nanoloiposomes with high affinity for Ab deposits: possible application to Alzheimer\u2019s disease","volume":"9","author":"Lazar","year":"2013","journal-title":"Nanomedicine"},{"key":"10.1016\/j.jconrel.2020.05.044_bb0660","doi-asserted-by":"crossref","first-page":"5892","DOI":"10.1074\/jbc.M404751200","article-title":"Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo","volume":"280","author":"Yang","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jconrel.2020.05.044_bb0665","doi-asserted-by":"crossref","first-page":"8370","DOI":"10.1523\/JNEUROSCI.21-21-08370.2001","article-title":"The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer\u2019s transgenic mouse","volume":"21","author":"Lim","year":"2001","journal-title":"J. Neurosci."},{"key":"10.1016\/j.jconrel.2020.05.044_bb0670","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.phrs.2017.08.004","article-title":"Curcumin in Alzheimer\u2019s disease: can we think to new strategies and perspectives for this molecule?","volume":"124","author":"Serafini","year":"2017","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.jconrel.2020.05.044_bb0675","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1097\/jcp.0b013e318160862c","article-title":"Six-month randomized, placebo-controlled, double-blind, pilot clinical trial of curcumin in patients with Alzheimer\u2019s disease","volume":"28","author":"Baum","year":"2008","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.jconrel.2020.05.044_bb0680","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.ijpharm.2011.06.030","article-title":"Curcumin and its nano-formulation: the kinetics of tissue distribution and blood-brain barrier penetration","volume":"416","author":"Tsai","year":"2011","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2020.05.044_bb0685","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1208\/s12248-012-9444-4","article-title":"Highly stabilized curcumin nanoparticles tested in an in vitro blood-brain model and in Alzheimer\u2019s disease Tg2576 mice","volume":"15","author":"Cheng","year":"2013","journal-title":"AAPS J."},{"key":"10.1016\/j.jconrel.2020.05.044_bb0690","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ejmech.2014.04.050","article-title":"Multifunctional nanoliposomes with curcumin-lipid derivative and brain targeting functionality with potential applications for Alzheimer\u2019s disease","volume":"80","author":"Mourtas","year":"2014","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.jconrel.2020.05.044_bb0695","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1021\/nn405077y","article-title":"Curcumin-loaded nanoparticles potently induce adult neurogenesis and reverse cognitive defecits in Alzheimer\u2019s disease model via canonical Wnt\/\u03b2-catenin pathway","volume":"8","author":"Tiwari","year":"2014","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2020.05.044_bb0700","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1002\/ana.410360510","article-title":"Oxidative damage to mitochondrial DNA is increased in Alzheimer\u2019s disease","volume":"36","author":"Mecocci","year":"1994","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jconrel.2020.05.044_bb0705","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/S0891-5849(96)00629-6","article-title":"Oxidative stress hypothesis in Alzheimer\u2019s disease","volume":"23","author":"Markesbery","year":"1997","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.jconrel.2020.05.044_bb0710","doi-asserted-by":"crossref","first-page":"7514","DOI":"10.1021\/jf049243r","article-title":"Protective effects of quercetin and vitamin C against oxidative stress-induced neurodegeneration","volume":"52","author":"Heo","year":"2004","journal-title":"J. Agri. Food Chem."},{"key":"10.1016\/j.jconrel.2020.05.044_bb0715","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.jnutbio.2008.03.002","article-title":"Protective effect of quercetin in primary neurons against Abeta(1\u201342): relevance to Alzheimer\u2019s disease","volume":"20","author":"Ansari","year":"2009","journal-title":"J. Nutr. Biochem."},{"key":"10.1016\/j.jconrel.2020.05.044_bb0720","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.ijpharm.2016.11.061","article-title":"Effect of oral administration of nanoencapsulated quercetin on a mouse model of Alzheimer\u2019s disease","volume":"517","author":"Puerta","year":"2017","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2020.05.044_bb0725","doi-asserted-by":"crossref","first-page":"480","DOI":"10.3844\/ajassp.2010.480.485","article-title":"Neuroprotective effect of quercetin encapsulated liposomes: a novel therapeutic strategy against Alzheimer\u2019s disease","volume":"7","author":"Phachonpai","year":"2010","journal-title":"Am. J. Appl. Sci."},{"key":"10.1016\/j.jconrel.2020.05.044_bb0730","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.colsurfb.2016.08.052","article-title":"Design of PLGA-functionalized nanoparticles for potential use in Alzheimer\u2019s disease","volume":"148","author":"Sun","year":"2016","journal-title":"Colloids Surf. B Biointerf."},{"key":"10.1016\/j.jconrel.2020.05.044_bb0735","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1248\/bpb.31.1392","article-title":"Prevention of inflammation-mediated neurotoxicity by Rg3 and its role in microglial activation","volume":"31","author":"Joo","year":"2008","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.jconrel.2020.05.044_bb0740","doi-asserted-by":"crossref","first-page":"457","DOI":"10.5142\/jgr.2011.35.4.457","article-title":"Improvement of cognitive deficit in Alzheimer\u2019s disease patients by long term treatment with Korean red ginseng","volume":"35","author":"Heo","year":"2011","journal-title":"J. Ginseng Res."},{"key":"10.1016\/j.jconrel.2020.05.044_bb0745","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.lfs.2014.12.002","article-title":"Neuroprotective effect of ginsenoside-Rg1 on cerebral ischemia\/reperfusion injury in rats by downregulating protease-activated receptor-1 expression","volume":"121","author":"Xie","year":"2015","journal-title":"Life Sci."},{"key":"10.1016\/j.jconrel.2020.05.044_bb0750","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.phymed.2013.12.005","article-title":"Ginsenoside Rg1 provides neuroprotection against blood-brain barrier disruption and neurological injury in a rat model of cerebral ischemia\/reperfusion through downregulation of aquaporin 4 expression","volume":"21","author":"Zhou","year":"2014","journal-title":"Phytomedicine"},{"key":"10.1016\/j.jconrel.2020.05.044_bb0755","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1080\/1061186X.2017.1354002","article-title":"Neuroprotective effects of a biodegradable poly(lactic-co-glycolic acid)-ginsenoside Rg3 nanoformulation: a potential nanotherapy for Alzheimer\u2019s disease?","volume":"26","author":"Aalinkeel","year":"2018","journal-title":"J. Drug Target."},{"key":"10.1016\/j.jconrel.2020.05.044_bb0760","doi-asserted-by":"crossref","first-page":"284","DOI":"10.3389\/fnagi.2018.00284","article-title":"Phyto-therapeutic and nanomedical approaches to cure Alzheimer\u2019s disease: present status and future opportunities","volume":"10","author":"Ovasis","year":"2018","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.jconrel.2020.05.044_bb0765","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.brainres.2013.02.026","article-title":"Huperzine A promotes hippocampal neurogenesis in vitro and in vivo","volume":"19","author":"Ma","year":"2013","journal-title":"Brain Res."},{"key":"10.1016\/j.jconrel.2020.05.044_bb0770","article-title":"Huperzine A for Alzheimer\u2019s disease: a systematic review and meta-analysis of randomized clinical trials","volume":"8","author":"Yang","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jconrel.2020.05.044_bb0775","doi-asserted-by":"crossref","first-page":"705","DOI":"10.2147\/IJN.S151474","article-title":"Intranasal delivery of Huperzine A to the brain using lactoferrin-conjugated N-trimethylated chitosan surface-modified PLGA nanoparticles for treatment of Alzheimer\u2019s disease","volume":"13","author":"Meng","year":"2018","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.jconrel.2020.05.044_bb0780","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1046\/j.1471-4159.1996.67051882.x","article-title":"Increased activity-regulating and neuroprotective efficacy of alpha-secretase-derived secreted amyloid precursor protein conferred by a C-terminal heparin-binding domain","volume":"67","author":"Furukawa","year":"1996","journal-title":"J. Neurochem."},{"key":"10.1016\/j.jconrel.2020.05.044_bb0785","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0165-0173(96)00014-8","article-title":"Cellular signalling roles of TGF beta, TNF alpha and beta APP in brain injury responses and Alzheimer\u2019s disease","volume":"23","author":"Mattson","year":"1997","journal-title":"Brain Res. Brain Res. Rev."},{"key":"10.1016\/j.jconrel.2020.05.044_bb0790","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.2174\/0929867023370121","article-title":"The search for \u03b1-secretase and its potential as a therapeutic approach to Alzheimer\u2019s disease","volume":"9","author":"Hooper","year":"2002","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.jconrel.2020.05.044_bb0795","doi-asserted-by":"crossref","first-page":"16419","DOI":"10.1074\/jbc.M600617200","article-title":"ADAM 10 activation is required for green tea (\u2212)-epigallocatechin-3-gallate induced alpha-secretase cleavage of amyloid precursor protein","volume":"281","author":"Obregon","year":"2006","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jconrel.2020.05.044_bb0800","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.ijpharm.2010.01.012","article-title":"Nanolipidic particles improve the bioavailability and \u03b1-secretase inducing ability of epigallocatechin-3-gallate (EGCG) for the treatment of Alzheimer\u2019s disease","volume":"389","author":"Smith","year":"2010","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2020.05.044_bb0805","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/0378-8741(82)90044-7","article-title":"Effect of Bacopa monniera Linn. (brahmi) extract on avoidance responses in rat","volume":"5","author":"Singh","year":"1982","journal-title":"J. Ethnopharmacol."},{"key":"10.1016\/j.jconrel.2020.05.044_bb0810","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jveb.2009.08.007","article-title":"Effect of Bacopa monniera Linn. (brahmi) extract on learning and memory in rats: a behavioural study","volume":"5","author":"Vollala","year":"2010","journal-title":"J. Vet. Behav."},{"key":"10.1016\/j.jconrel.2020.05.044_bb0815","doi-asserted-by":"crossref","first-page":"95","DOI":"10.4103\/0974-8520.115441","article-title":"A comparative pharmacognostical and preliminary physico-chemical analysis of stem and leaf of Bacopa monnieri (L.) and Bacopa floribunda (R.BR.)","volume":"34","author":"Gubbannavar","year":"2013","journal-title":"Wettst. Ayu."},{"key":"10.1016\/j.jconrel.2020.05.044_bb0820","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.jep.2008.07.039","article-title":"Neuroprotective effect of Bacopa monnieri on beta-amyloid induced cell death in primary cortical culture","volume":"120","author":"Limpeanchob","year":"2008","journal-title":"J. Ethnopharmacol."},{"key":"10.1016\/j.jconrel.2020.05.044_bb0825","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ejps.2014.06.024","article-title":"Surface modified PLGA nanoparticles for brain targeting of bacoside-A","volume":"63","author":"Jose","year":"2014","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2020.05.044_bb0830","first-page":"2596","article-title":"Resveratrol increases nitric oxide synthase, induces accumulation of p53 and p21 WAF1\/CIP1, and suppresses cultured bovine pulmonary artery endothelial cell proliferation by perturbing progression through S and G2","volume":"59","author":"Hsieh","year":"1999","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2020.05.044_bb0835","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0304-3940(01)01654-8","article-title":"Anti-apoptotic effect of trans-reseratrol on paclitaxel-induced apoptosis in the human neuroblastoma SH-SY5Y cell line","volume":"302","author":"Nicolini","year":"2001","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.jconrel.2020.05.044_bb0840","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1159\/000073766","article-title":"Red wine ingredient resveratrol protects from beta-amyloid neurotoxicity","volume":"49","author":"Savaskan","year":"2003","journal-title":"Gerontology"},{"key":"10.1016\/j.jconrel.2020.05.044_bb0845","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0304-3940(00)00820-X","article-title":"Partial neuroprotection of in vivo excitotoxic brain damage by chronic administration of the red wine antioxidant agent, trans-resveratrol in rats","volume":"281","author":"Virgili","year":"2000","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.jconrel.2020.05.044_bb0850","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ijpharm.2009.03.021","article-title":"Resveratrol-loaded polymeric micelles protect cells from Abeta-induced oxidative stress","volume":"375","author":"Lu","year":"2009","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2020.05.044_bb0855","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.3109\/10717544.2015.1092619","article-title":"Development of an optimized hyaluronic acid-based lipidic nanoemulsion co-encapsulating two polyphenols for nose to brain delivery","volume":"23","author":"Nasr","year":"2016","journal-title":"Drug Deliv."},{"key":"10.1016\/j.jconrel.2020.05.044_bb0860","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/j.fct.2009.12.009","article-title":"Piperine, the main alkaloid of Thai black pepper, protects against neurodegeneration and cognitive impairment in animal model of cognitive deficit like condition of Alzheimer\u2019s disease","volume":"48","author":"Chonpathompikunlert","year":"2010","journal-title":"Food Chem. Toxicol."},{"key":"10.1016\/j.jconrel.2020.05.044_bb0865","doi-asserted-by":"crossref","first-page":"3544","DOI":"10.1002\/jps.24557","article-title":"Intranasal piperine loaded chitosan nanoparticles as brain-targeted therapy in Alzheimer\u2019s disease: optimization, biological efficacy, and potential toxicity","volume":"104","author":"Elnaggar","year":"2015","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2020.05.044_bb0870","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S0197-0186(02)00050-5","article-title":"A\u03b2 toxicity in Alzheimer\u2019s disease: globular oligomers (ADDLs) as new vaccine and drug targets","volume":"41","author":"Klein","year":"2002","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.jconrel.2020.05.044_bb0875","doi-asserted-by":"crossref","first-page":"25945","DOI":"10.1074\/jbc.274.36.25945","article-title":"Amyloid -\u03b2 protein fibrillogenesis. Structure and biological activity of protofibrillar intermediaes","volume":"274","author":"Walsh","year":"1999","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jconrel.2020.05.044_bb0880","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.biopsych.2017.08.010","article-title":"Anti-amyloid-\u03b2 monoclonal antibodies for Alzheimer\u2019s disease: pitfalls and promise","volume":"83","author":"van Dyck","year":"2018","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.jconrel.2020.05.044_bb0885","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1212\/01.WNL.0000159740.16984.3C","article-title":"Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial","volume":"64","author":"Gilman","year":"2005","journal-title":"Neurology"}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365920303217?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365920303217?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T15:48:51Z","timestamp":1759160931000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365920303217"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":177,"alternative-id":["S0168365920303217"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2020.05.044","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neurotherapeutic applications of nanomedicine for treating Alzheimer's disease","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2020.05.044","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}